Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell's viper venom time to lupus anticoagulants

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 3, 2004, Pages 279-282

  Moore, Gary W ^a   Savidge, Geoffrey F ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Biological variability; Dilute Russell's viper venom time; Heterogeneity; Lupus anticoagulant

Indexed keywords

LUPUS ANTICOAGULANT; PHOSPHOLIPID; REAGENT; RUSSELL VIPER VENOM TIME REAGENT; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING TEST; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DILUTION; HUMAN; PRIORITY JOURNAL; RUSSELL VIPER VENOM TIME; SCREENING; THROMBOPHILIA; VARIANCE;

FALSE NEGATIVE REACTIONS; HUMANS; INDICATORS AND REAGENTS; LUPUS COAGULATION INHIBITOR; PROTHROMBIN TIME; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; VIPER VENOMS;

EID: 2342432617     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200404000-00015     Document Type: Article

References (27)

1. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86:83-91.
2. Bick RL. The antiphospholipid thrombosis syndromes: a common multi-disciplinary medical problem. Clin Appl Thromb/Haemost 1997; 3:270-283.
3. Triplett DA. New diagnostic strategies for lupus anticoagulants and antiphospholipid antibodies. Haemostasis 1994; 24:155-164.
4. Machin SJ, Giddings JC, Greaves M, Hutton RA, Mackie IJ, Malia RG, Taberner DA. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44:885-889.
5. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109:704-715.
6. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74:1185-1190.
7. Triplett DA. Frequent difficulties encountered in the laboratory diagnosis of antiphospholipid-protein antibodies. Ann Med Interne 1996; 147(suppl 1):5-9.
8. Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK national external quality control scheme (NEQAS) for blood coagulation. Thromb Haemost 1997; 77:934-937.
9. UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Report on Survey 128. Sheffield: NEQAS; 2001.
10. Lawrie AS, Mackie IJ, Purdy G, Machin SJ. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999; 81:758-762.
11. Mackie IJ, Gardiner C, Machin SJ, Greaves M, Malia R, Jones DW, et al. Medical Devices Agency Evaluation Report Three lupus anticoagulant kits, MDA/98/43. Norwich: HMSO; 1998.
12. Stevenson KJ, Seddon JM. The role of lipids in the detection of lupus anticoagulant by the dilute Russell Viper venom test: are platelets or reagents containing hexagonal HII phases necessary? Br J Haematol 1994; 86:583-589.
13. Amiral J. Diagnostic approach of phospholipid-dependent antibodies. State-of-the-art lecture. Haemostesis 1999; 29:135-149.
14. Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000; 15:173-178.
15. Haemostasis Committee of the 'Societe Francaise de Biologie Clinique'. Laboratory heterogeneity of the lupus anticoagulant: a multicentre study using different clotting assays on a panel of samples. Thromb Res 1992; 66:349-364.
16. Nakamura N, Azuma C, Akamizu T, Sugawa H, Matsuda F, Mitsuda N, et al. Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with systemic lupus erythematosus. Biochem Biophys Res Commun 1994; 203:1789-1794.
17. Kandiah DA, Krillis SA. Heterogeneity of lupus anticoagulants (LA) antibodies: LA activity in dilute Russell's Viper Venom Time and dilute Kaolin Clotting Time detect different populations of antibodies in patients with the 'antiphospholipid' syndrome. Thromb Haemost 1998; 80:250-257.
18. Gardiner C, Mackie IJ, Malia RG, Jones DW, Winter M, Leeming D, Tabemer DA. The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br J Haematol 2000; 111:1230-1235.
19. Prasad NB, Uma B, Bhatt SK, Gowda VT. Comparative characteristation of Russell's viper (Daboia/Vipera russelli) venoms from different regions of the Indian peninsula. Biochim Biophys Acta 1999; 1428:121-136.
20. Jayanthi GP, Gowda TV. Geographical variation in India in the composition and lethal potency of Russell's viper (Vipera russelli) venom. Toxicon 1988; 26:257-264.
21. Chippaux JP, Williams V, White J. Snake venom variability: methods of study, results and interpretation. Toxicon 1991; 29:1279-1303.
22. Tun-Pe, Nu-Nu-Lwin, Aye-Aye-Myint, Kyi-May-Htwe, Khin-Aung-Cho. Biochemical and biological properties of the venom from Russell's viper (Daboia russelli siamensis) of varying ages. Toxicon 1995; 33:817-821.
23. Daltry JC, Wüster W, Thorpe RS. Diet and snake venom evolution. Nature 1996; 379:537-540.
24. Foster WM, Triplett DA, Ieko M, Barna LK. Analysis of Russell viper venom (RVV) by SDS-PAGE [abstract 158]. Lupus 1994; 3:352.
25. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002; 119:364-369.
26. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:1827-1832.
27. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7:15-22.